Pharmacological Strategies to Reduce Cardiovascular Risk in Type 2 Diabetes Mellitus Marcel M. C. HovensJouke T. TamsmaMenno V. Huisman Leading Article 17 September 2012 Pages: 433 - 445
New Treatment Modalities for Vitiligo Kresimir KostovicAida Pasic Leading Article 17 September 2012 Pages: 447 - 459
Adverse Effects and Drug Interactions of Antithrombotic Agents Used in Prevention of Ischaemic Stroke Jesse Weinberger Review Article 17 September 2012 Pages: 461 - 471
An Overview of Economic Evaluations for Drugs Used in Rheumatoid Arthritis Nick J. BansbackDean A. RegierCarlo A. Marra Review Article 17 September 2012 Pages: 473 - 496
Management of Sight-Threatening Uveitis Matthias D. BeckerJustine R. SmithChristoph Fiehn Review Article 17 September 2012 Pages: 497 - 519
Peginterferon α-2a (40KD) Plus Ribavirin Gillian M. KeatingGreg L. Plosker Adis Drug Evaluation 17 September 2012 Pages: 521 - 536
Candesartan Cilexetil Caroline FentonLesley J. Scott Adis Drug Evaluation 17 September 2012 Pages: 537 - 558
5-Lipoxygenase as a Putative Mechanism of NSAID-Related Psychiatric Adverse Events Radmila ManevHari Manev Letter to the Editor 17 September 2012 Pages: 577 - 577